| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adhesion molecules and gene transfer
|
Parkes, Richard J
|
|
2000
|
69-70 |
2-3 |
p. 135-152
18 p.
|
artikel
|
| 2 |
Adv. Drug Delivery Rev.
|
Welt, Frederick G.P.
|
|
1997
|
69-70 |
2-3 |
p. 299-
1 p.
|
artikel
|
| 3 |
Amphotericin B colloidal dispersion: an improved antifungal therapy
|
Guo, Luke S.S
|
|
2001
|
69-70 |
2-3 |
p. 149-163
15 p.
|
artikel
|
| 4 |
Amphotericin B encapsulated in polyethylene glycol-immunoliposomes for infectious diseases
|
Kohno, Shigeru
|
|
1997
|
69-70 |
2-3 |
p. 325-329
5 p.
|
artikel
|
| 5 |
Analytical challenges in chemical-enzymatic drug targeting
|
Prókai, László
|
|
1994
|
69-70 |
2-3 |
p. 301-317
17 p.
|
artikel
|
| 6 |
Analytical considerations for microdialysis sampling
|
Davies, Malonne I
|
|
2000
|
69-70 |
2-3 |
p. 169-188
20 p.
|
artikel
|
| 7 |
A novel chemical delivery system for brain targeting
|
Yoshikawa, Takayoshi
|
|
1999
|
69-70 |
2-3 |
p. 255-275
21 p.
|
artikel
|
| 8 |
Antibody-directed enzyme prodrug therapy (ADEPT): a review
|
Niculescu-Duvaz, I
|
|
1997
|
69-70 |
2-3 |
p. 151-172
22 p.
|
artikel
|
| 9 |
Antibody-targeted liposomes: prospects and problems
|
Allen, T.M.
|
|
1997
|
69-70 |
2-3 |
p. 243-
1 p.
|
artikel
|
| 10 |
Application of lipid microspheres for the treatment of cancer
|
Takenaga, Mitsuko
|
|
1996
|
69-70 |
2-3 |
p. 209-219
11 p.
|
artikel
|
| 11 |
Application of liposomes for cancer metastasis
|
Oku, Naoto
|
|
1997
|
69-70 |
2-3 |
p. 215-223
9 p.
|
artikel
|
| 12 |
Application of liposomes to the treatment of liver metastasis
|
Konno, Hiroyuki
|
|
1997
|
69-70 |
2-3 |
p. 331-335
5 p.
|
artikel
|
| 13 |
Application of microdialysis to characterize drug disposition in tumors
|
Chu, Jianxiong
|
|
2000
|
69-70 |
2-3 |
p. 243-253
11 p.
|
artikel
|
| 14 |
Approved indications of lipo-PGE1 in Japan
|
Hoshi, K.
|
|
1996
|
69-70 |
2-3 |
p. 171-176
6 p.
|
artikel
|
| 15 |
A preclinical assessment of the effect of lipo-PGE1 on thrombus formation and thrombus disaggregation
|
Sim, A.K.
|
|
1996
|
69-70 |
2-3 |
p. 165-170
6 p.
|
artikel
|
| 16 |
A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-α and cytotoxic agents
|
ten Hagen, Timo L.M.
|
|
1997
|
69-70 |
2-3 |
p. 245-256
12 p.
|
artikel
|
| 17 |
Biohybrid artificial pancreas based on macrocapsule device
|
Hou, Q.P
|
|
1999
|
69-70 |
2-3 |
p. 271-287
17 p.
|
artikel
|
| 18 |
Biological factors involved in blood clearance of liposomes by liver
|
Liu, Dexi
|
|
1997
|
69-70 |
2-3 |
p. 201-213
13 p.
|
artikel
|
| 19 |
Block copolymer micelles as long-circulating drug vehicles
|
Kwon, Glen S.
|
|
1995
|
69-70 |
2-3 |
p. 295-309
15 p.
|
artikel
|
| 20 |
Blood-brain barrier function of P-glycoprotein
|
Tsuji, Akira
|
|
1997
|
69-70 |
2-3 |
p. 287-298
12 p.
|
artikel
|
| 21 |
Blood–brain barrier permeability to small and large molecules
|
Cornford, Eain M.
|
|
1999
|
69-70 |
2-3 |
p. 145-163
19 p.
|
artikel
|
| 22 |
Blood microdialysis in pharmacokinetic and drug metabolism studies
|
Verbeeck, Roger K
|
|
2000
|
69-70 |
2-3 |
p. 217-228
12 p.
|
artikel
|
| 23 |
Carrier-mediated or specialized transport of drugs across the blood–brain barrier
|
Tsuji, Akira
|
|
1999
|
69-70 |
2-3 |
p. 277-290
14 p.
|
artikel
|
| 24 |
Cationic lipid–DNA complexes in gene delivery: from biophysics to biological applications
|
Pedroso de Lima, Maria C
|
|
2001
|
69-70 |
2-3 |
p. 277-294
18 p.
|
artikel
|
| 25 |
Cell cycle regulation and control of angioplasty restenosis
|
Welt, Frederick G.P.
|
|
1997
|
69-70 |
2-3 |
p. 301-307
7 p.
|
artikel
|
| 26 |
Challenges of turning nucleic acids into therapeutics
|
Mahato, Ram I
|
|
2000
|
69-70 |
2-3 |
p. 79-80
2 p.
|
artikel
|
| 27 |
Chemical delivery systems and prodrugs of anticonvulsive drugs
|
Shek, Efraim
|
|
1994
|
69-70 |
2-3 |
p. 227-241
15 p.
|
artikel
|
| 28 |
Chemistry of polyethylene glycol conjugates with biologically active molecules
|
Zalipsky, Samuel
|
|
1995
|
69-70 |
2-3 |
p. 157-182
26 p.
|
artikel
|
| 29 |
Compartment modeling
|
Holz, Martin
|
|
2001
|
69-70 |
2-3 |
p. 249-264
16 p.
|
artikel
|
| 30 |
Computer-assisted drug design and selection
|
Kaminski, James J.
|
|
1994
|
69-70 |
2-3 |
p. 331-337
7 p.
|
artikel
|
| 31 |
Contents of volume 14
|
|
|
1994
|
69-70 |
2-3 |
p. 341-342
2 p.
|
artikel
|
| 32 |
Contents of volume 8
|
|
|
1992
|
69-70 |
2-3 |
p. 383-
1 p.
|
artikel
|
| 33 |
Contents of volume 10
|
|
|
1993
|
69-70 |
2-3 |
p. 319-
1 p.
|
artikel
|
| 34 |
Contents of volume 9
|
|
|
1992
|
69-70 |
2-3 |
p. 318-
1 p.
|
artikel
|
| 35 |
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
|
Hebert, M.F
|
|
1997
|
69-70 |
2-3 |
p. 201-214
14 p.
|
artikel
|
| 36 |
Control-relevant modeling in drug delivery
|
Parker, Robert S.
|
|
2001
|
69-70 |
2-3 |
p. 211-228
18 p.
|
artikel
|
| 37 |
Cubic phase gels as drug delivery systems
|
Shah, Jaymin C
|
|
2001
|
69-70 |
2-3 |
p. 229-250
22 p.
|
artikel
|
| 38 |
Cumulative author index
|
|
|
1992
|
69-70 |
2-3 |
p. 367-374
8 p.
|
artikel
|
| 39 |
Cumulative key word index
|
|
|
1994
|
69-70 |
2-3 |
p. 343-355
13 p.
|
artikel
|
| 40 |
Cumulative key word index
|
|
|
1993
|
69-70 |
2-3 |
p. 309-317
9 p.
|
artikel
|
| 41 |
Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment 1 Abbreviations: AIA, antiinsulin antibody; CAPD, continuous ambulatory dialysis; CSII, continuous subcutaneous insulin infusion; DCCT, diabetes control complications trial; FIR, far infrared radiation; GLP1, glucagon-like peptide 1; GH, growth hormone; HbA1c, glycated hemoglobin; IDDM, insulin-dependent diabetes mellitus; IGF1, insulin-like growth factor 1; i.p., intraperitoneal; ISF, interstitial fluid; ISGIID, International Study Group on Implantable Insulin Delivery Devices; i.v., intravenous; MDI, multiple daily injections; NIDDM, non-insulin-dependent diabetes mellitus; PAI1, plasminogen activator inhibitor 1; rh IGF1, recombinant human insulin-like growth factor 1; SHBG, sex hormone binding globulin; SC, subcutaneous; SMBG, self monitoring of blood glucose; TG, triglycerides. 1
|
Jeandidier, Nathalie
|
|
1999
|
69-70 |
2-3 |
p. 179-198
20 p.
|
artikel
|
| 42 |
Delivery of anti-HIV nucleosides to the central nervous system
|
Gallo, James M.
|
|
1994
|
69-70 |
2-3 |
p. 199-209
11 p.
|
artikel
|
| 43 |
Delivery of molecular and cellular medicine to solid tumors
|
Jain, Rakesh K
|
|
1997
|
69-70 |
2-3 |
p. 71-90
20 p.
|
artikel
|
| 44 |
Delivery of peptides and proteins through the blood-brain barrier
|
Bickel, Ulrich
|
|
1993
|
69-70 |
2-3 |
p. 205-245
41 p.
|
artikel
|
| 45 |
Delivery of tumor suppressor genes to reverse the malignant phenotype
|
Gibson, Neil W
|
|
1997
|
69-70 |
2-3 |
p. 119-133
15 p.
|
artikel
|
| 46 |
Distribution of lipid microsphere preparations
|
Igarashi, R.
|
|
1996
|
69-70 |
2-3 |
p. 147-154
8 p.
|
artikel
|
| 47 |
DNA-carrier proteins for targeted gene delivery
|
Uherek, Christoph
|
|
2000
|
69-70 |
2-3 |
p. 153-166
14 p.
|
artikel
|
| 48 |
(D) Routes of delivery: Case studies
|
de Boer, A.G.
|
|
1992
|
69-70 |
2-3 |
p. 237-251
15 p.
|
artikel
|
| 49 |
(D) Routes of delivery: Case studies
|
Richardson, Julie L.
|
|
1992
|
69-70 |
2-3 |
p. 341-366
26 p.
|
artikel
|
| 50 |
(D) Routes of delivery: Case studies
|
Harris, David
|
|
1992
|
69-70 |
2-3 |
p. 331-339
9 p.
|
artikel
|
| 51 |
(D) Routes of delivery: Case studies
|
Ho, N.F.H.
|
|
1992
|
69-70 |
2-3 |
p. 197-236
40 p.
|
artikel
|
| 52 |
(D) Routes of delivery: Case studies
|
Edman, Peter
|
|
1992
|
69-70 |
2-3 |
p. 165-177
13 p.
|
artikel
|
| 53 |
(D) Routes of delivery: Case studies
|
Smith, Philip L.
|
|
1992
|
69-70 |
2-3 |
p. 253-290
38 p.
|
artikel
|
| 54 |
(D) Routes of delivery: Case studies
|
Cullander, Christopher
|
|
1992
|
69-70 |
2-3 |
p. 291-329
39 p.
|
artikel
|
| 55 |
(D) Routes of delivery: Case studies
|
Patton, John S.
|
|
1992
|
69-70 |
2-3 |
p. 179-196
18 p.
|
artikel
|
| 56 |
Drug design strategies for ocular therapeutics
|
Visor, G.C.
|
|
1994
|
69-70 |
2-3 |
p. 269-279
11 p.
|
artikel
|
| 57 |
Drug targeting and retrometabolic drug design approaches Introduction
|
Bodor, N.
|
|
1994
|
69-70 |
2-3 |
p. 157-166
10 p.
|
artikel
|
| 58 |
Drug transfer through mucus
|
Khanvilkar, Kavita
|
|
2001
|
69-70 |
2-3 |
p. 173-193
21 p.
|
artikel
|
| 59 |
Editorial
|
|
|
1997
|
69-70 |
2-3 |
p. 97-98
2 p.
|
artikel
|
| 60 |
Editorial
|
|
|
1998
|
69-70 |
2-3 |
p. 121-
1 p.
|
artikel
|
| 61 |
Editorial
|
|
|
1999
|
69-70 |
2-3 |
p. 141-142
2 p.
|
artikel
|
| 62 |
Editorial
|
|
|
1999
|
69-70 |
2-3 |
p. 143-144
2 p.
|
artikel
|
| 63 |
Editorial Board
|
|
|
2007
|
69-70 |
2-3 |
p. ii-
1 p.
|
artikel
|
| 64 |
Electrochemotherapy: an emerging drug delivery method for the treatment of cancer
|
Jaroszeski, Mark J
|
|
1997
|
69-70 |
2-3 |
p. 185-197
13 p.
|
artikel
|
| 65 |
Emulsion formulations as a vector for gene delivery in vitro and in vivo
|
Hara, Toshifumi
|
|
1997
|
69-70 |
2-3 |
p. 265-271
7 p.
|
artikel
|
| 66 |
Endogenous carriers and ligands in non-immunogenic site-specific drug delivery
|
Vyas, S.P
|
|
2000
|
69-70 |
2-3 |
p. 101-164
64 p.
|
artikel
|
| 67 |
Endogenous lectins as targets for drug delivery
|
Yamazaki, N.
|
|
2000
|
69-70 |
2-3 |
p. 225-244
20 p.
|
artikel
|
| 68 |
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
|
Thummel, Kenneth E.
|
|
1997
|
69-70 |
2-3 |
p. 99-127
29 p.
|
artikel
|
| 69 |
Evaluation of an estradiol chemical delivery system (CDS) designed to provide enhanced and sustained hormone levels in the brain
|
Estes, K.S.
|
|
1994
|
69-70 |
2-3 |
p. 167-175
9 p.
|
artikel
|
| 70 |
Evaluation of nano- and microparticle uptake by the gastrointestinal tract
|
Delie, Florence
|
|
1998
|
69-70 |
2-3 |
p. 221-233
13 p.
|
artikel
|
| 71 |
Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides
|
Meade, Bryan R.
|
|
2007
|
69-70 |
2-3 |
p. 134-140
7 p.
|
artikel
|
| 72 |
Exogenous surfactant as a drug delivery agent
|
Haitsma, Jack J.
|
|
2001
|
69-70 |
2-3 |
p. 197-207
11 p.
|
artikel
|
| 73 |
Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research
|
Krafft, Marie Pierre
|
|
2001
|
69-70 |
2-3 |
p. 209-228
20 p.
|
artikel
|
| 74 |
Forthcoming articles
|
|
|
1992
|
69-70 |
2-3 |
p. 375-
1 p.
|
artikel
|
| 75 |
Forthcoming articles
|
|
|
1993
|
69-70 |
2-3 |
p. 301-303
3 p.
|
artikel
|
| 76 |
Forthcoming articles
|
|
|
1992
|
69-70 |
2-3 |
p. 313-314
2 p.
|
artikel
|
| 77 |
Forthcoming events
|
|
|
1992
|
69-70 |
2-3 |
p. 377-382
6 p.
|
artikel
|
| 78 |
Forthcoming events
|
|
|
1992
|
69-70 |
2-3 |
p. 315-317
3 p.
|
artikel
|
| 79 |
Forthcoming events
|
|
|
1994
|
69-70 |
2-3 |
p. 340-
1 p.
|
artikel
|
| 80 |
Forthcoming events
|
|
|
1993
|
69-70 |
2-3 |
p. 305-307
3 p.
|
artikel
|
| 81 |
Forthcoming issues
|
|
|
1994
|
69-70 |
2-3 |
p. 339-
1 p.
|
artikel
|
| 82 |
Gene directed enzyme prodrug therapy for cancer
|
McNeish, I.A
|
|
1997
|
69-70 |
2-3 |
p. 173-184
12 p.
|
artikel
|
| 83 |
Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications
|
Kumar, Lekha Dinesh
|
|
2007
|
69-70 |
2-3 |
p. 87-100
14 p.
|
artikel
|
| 84 |
Gene therapy of chronic inflammatory disease
|
Hedley, Mary Lynne
|
|
2000
|
69-70 |
2-3 |
p. 195-207
13 p.
|
artikel
|
| 85 |
Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters
|
Meijer, D.K.F.
|
|
1997
|
69-70 |
2-3 |
p. 159-200
42 p.
|
artikel
|
| 86 |
How are nucleic acids released in cells from cationic lipid-nucleic acid complexes?
|
Szoka Jr, Francis C.
|
|
1997
|
69-70 |
2-3 |
p. 291-
1 p.
|
artikel
|
| 87 |
Human immunodeficiency virus protease inhibitors
|
Lin, Jiunn H.
|
|
1997
|
69-70 |
2-3 |
p. 215-233
19 p.
|
artikel
|
| 88 |
Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs
|
Storm, Gert
|
|
1997
|
69-70 |
2-3 |
p. 225-231
7 p.
|
artikel
|
| 89 |
Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs 1 Supported by the Robert Bosch Foundation, Stuttgart, Germany. 1
|
Fromm, Martin F
|
|
1997
|
69-70 |
2-3 |
p. 171-199
29 p.
|
artikel
|
| 90 |
Improved brain delivery of antiviral agents through the use of redox targeting
|
Brewster, M.E.
|
|
1994
|
69-70 |
2-3 |
p. 177-197
21 p.
|
artikel
|
| 91 |
Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies
|
Pauletti, Giovanni M.
|
|
1997
|
69-70 |
2-3 |
p. 235-256
22 p.
|
artikel
|
| 92 |
Inhaled insulin 1 Abbreviations: DM, diabetes mellitus; AIDs, acquired immune deficiency syndrome; SC, subcutaneous; DCCT, Diabetes Control and Complications Trial; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus; i.v., intravenous; DDPC, di-decanoyl-alpha-phosphatidylcholine; AUC, area under the curve; INH, inhaled; C max, maximum serum concentration; C min, minimum serum concentration; T max, time of maximum serum concentration; NS, not significant; HbA1c, hemoglobin A1c; OA, oral agent; SD, standard deviation; MDI, metered dose inhaler; DPI, dry powder inhaler; MMAD, mass median aerodynamic diameter; CMC, critical micelle concentration; SR, sustained release; PLGA, poly lactic acid-co-glycolic acid; GI, gastrointestinal, GSD, geometric standard deviation; TLC, total lung capacity; VC, vital capacity; SMK, smokers; MW, molecular weight; MP, melting point. 1
|
Patton, John S.
|
|
1999
|
69-70 |
2-3 |
p. 235-247
13 p.
|
artikel
|
| 93 |
Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents
|
Eileen Dolan, M
|
|
1997
|
69-70 |
2-3 |
p. 105-118
14 p.
|
artikel
|
| 94 |
Inhibitors of glutathione S-transferases as therapeutic agents
|
Schultz, Mary
|
|
1997
|
69-70 |
2-3 |
p. 91-104
14 p.
|
artikel
|
| 95 |
Insulin analogs with improved pharmacokinetic profiles
|
Brange, Jens
|
|
1999
|
69-70 |
2-3 |
p. 307-335
29 p.
|
artikel
|
| 96 |
Interaction of PEG-phospholipid conjugates with phospholipid: implications in liposomal drug delivery
|
Bedu-Addo, Frank K.
|
|
1995
|
69-70 |
2-3 |
p. 235-247
13 p.
|
artikel
|
| 97 |
Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
|
Hunter, Janice
|
|
1997
|
69-70 |
2-3 |
p. 129-157
29 p.
|
artikel
|
| 98 |
Intranasal insulin delivery and therapy 1 Abbreviations: α-CD, α-cyclodextrin; β-CD, β-cyclodextrin; γ-CD, γ-cyclodextrin; AUC, area under the plasma/serum concentration versus time curve; C max, maximum or peak plasma/serum concentration; C min, minimum plasma/serum concentration; DDPC, didecanoyl-L-α-phosphatidylcholine; DM-β-CD, dimethyl-β-cyclodextrin; EDTA, ethylenediaminetetraacetic acid; FITC, fluorescein isothiocyanate; HLB, hydrophile–lipophile balance; hGH, human growth hormone; HP-β-CD, hydroxy-propyl-β-cyclodextrin; HPC, hydroxypropylcellulose; HSA, human serum albumin; Hyaff 11, hyaluronic acid ester; IDDM, insulin-dependent diabetes mellitus; Ig, immunoglobulin; Laureth-9, polyoxyethylene-9-lauryl ether; LPC, lysophosphatidylcholine; LPG, lysophosphatidylglycerol; MCC, microcrystalline cellulose; MTR, mucociliary transport rate; NIDDM, non-insulin-dependent diabetes mellitus; PC, phosphatidylcholine; RAMEB, randomly methylated β-cyclodextrin; SDC, sodium deoxycholate; SGC, sodium glycocholate; STDHF, sodium taurodihydrofusidate; 99mTc, 99mtechnetium; TER, transepithelial resistance. 1
|
Hinchcliffe, Michael
|
|
1999
|
69-70 |
2-3 |
p. 199-234
36 p.
|
artikel
|
| 99 |
In vitro model for evaluating drug transport across the blood–brain barrier
|
Cecchelli, R
|
|
1999
|
69-70 |
2-3 |
p. 165-178
14 p.
|
artikel
|
| 100 |
Key word index to volume 9
|
|
|
1992
|
69-70 |
2-3 |
p. 309-312
4 p.
|
artikel
|
| 101 |
Lectin-mediated mucosal delivery of drugs and microparticles
|
Clark, M.Ann
|
|
2000
|
69-70 |
2-3 |
p. 207-223
17 p.
|
artikel
|
| 102 |
Ligand-mediated tissue specific drug delivery
|
Hussain, Nasir
|
|
2000
|
69-70 |
2-3 |
p. 95-100
6 p.
|
artikel
|
| 103 |
Limethason as a lipid microsphere preparation: An overview
|
Yokoyama, K.
|
|
1996
|
69-70 |
2-3 |
p. 195-201
7 p.
|
artikel
|
| 104 |
Lipid Assemblies for Drug Delivery
|
|
|
2001
|
69-70 |
2-3 |
p. 137-138
2 p.
|
artikel
|
| 105 |
Lipid/DNA complexes as an intermediate in the preparation of particles for gene transfer: an alternative to cationic liposome/DNA aggregates
|
Bally, Marcel B.
|
|
1997
|
69-70 |
2-3 |
p. 275-290
16 p.
|
artikel
|
| 106 |
Lipid microsphere preparation of a prostacyclin analogue
|
Kurozumi, S.
|
|
1996
|
69-70 |
2-3 |
p. 181-187
7 p.
|
artikel
|
| 107 |
Lipid microspheres as drug carriers: a pharmaceutical point of view
|
Yamaguchi, Tetsuo
|
|
1996
|
69-70 |
2-3 |
p. 117-130
14 p.
|
artikel
|
| 108 |
Lipid microspheres (lipid emulsions) as a drug carrier — An overview
|
Mizushima, Yutaka
|
|
1996
|
69-70 |
2-3 |
p. 113-115
3 p.
|
artikel
|
| 109 |
Lipo-NSAID preparation
|
Ohmukai, O.
|
|
1996
|
69-70 |
2-3 |
p. 203-207
5 p.
|
artikel
|
| 110 |
Lipo-PGE1 treatment of the neonate with critical congenital heart disease and ductus-arteriosus dependent circulation
|
Momma, Kazuo
|
|
1996
|
69-70 |
2-3 |
p. 177-180
4 p.
|
artikel
|
| 111 |
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
|
Gabizon, Alberto A.
|
|
1995
|
69-70 |
2-3 |
p. 285-294
10 p.
|
artikel
|
| 112 |
Liposomes in gene therapy
|
Lasic, D.D.
|
|
1996
|
69-70 |
2-3 |
p. 221-266
46 p.
|
artikel
|
| 113 |
Liposome turbidimetric assay (LTA)
|
Ueno, Takahisa
|
|
1997
|
69-70 |
2-3 |
p. 293-299
7 p.
|
artikel
|
| 114 |
Local delivery of chemotherapy: a supplement to existing cancer treatments
|
Hunter, William L
|
|
1997
|
69-70 |
2-3 |
p. 199-207
9 p.
|
artikel
|
| 115 |
Long-circulating blood pool imaging agents
|
Bogdanov Jr., Alexei A.
|
|
1995
|
69-70 |
2-3 |
p. 335-348
14 p.
|
artikel
|
| 116 |
Long-circulating iron oxides for MR imaging
|
Weissleder, Ralph
|
|
1995
|
69-70 |
2-3 |
p. 321-334
14 p.
|
artikel
|
| 117 |
Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
|
Gabizon, Alberto
|
|
1997
|
69-70 |
2-3 |
p. 337-344
8 p.
|
artikel
|
| 118 |
Long circulating microparticulate drug carriers
|
Stolnik, S.
|
|
1995
|
69-70 |
2-3 |
p. 195-214
20 p.
|
artikel
|
| 119 |
Mathematical modeling of bioerodible, polymeric drug delivery systems
|
Siepmann, J.
|
|
2001
|
69-70 |
2-3 |
p. 229-247
19 p.
|
artikel
|
| 120 |
Mathematical modeling of controlled drug delivery
|
|
|
2001
|
69-70 |
2-3 |
p. 137-138
2 p.
|
artikel
|
| 121 |
Mathematical models describing polymer dissolution: consequences for drug delivery
|
Narasimhan, Balaji
|
|
2001
|
69-70 |
2-3 |
p. 195-210
16 p.
|
artikel
|
| 122 |
MDR2 P-glycoprotein-mediated lipid secretion and its relevance to biliary drug transport
|
Frijters, Charles M.G.
|
|
1997
|
69-70 |
2-3 |
p. 201-215
15 p.
|
artikel
|
| 123 |
Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers
|
Moghimi, S.M.
|
|
1995
|
69-70 |
2-3 |
p. 183-193
11 p.
|
artikel
|
| 124 |
Methodological issues in microdialysis sampling for pharmacokinetic studies
|
de Lange, Elizabeth C.M.
|
|
2000
|
69-70 |
2-3 |
p. 125-148
24 p.
|
artikel
|
| 125 |
Microdialysis and drug delivery to the eye
|
Rittenhouse, Kay D
|
|
2000
|
69-70 |
2-3 |
p. 229-241
13 p.
|
artikel
|
| 126 |
Microdialysis for pharmacokinetic analysis of drug transport to the brain
|
de Lange, Elizabeth C.M.
|
|
1999
|
69-70 |
2-3 |
p. 211-227
17 p.
|
artikel
|
| 127 |
Microdialysis in clinical drug delivery studies
|
Müller, Markus
|
|
2000
|
69-70 |
2-3 |
p. 255-269
15 p.
|
artikel
|
| 128 |
Microdialysis in mice for drug delivery research
|
Boschi, Gabrielle
|
|
2000
|
69-70 |
2-3 |
p. 271-281
11 p.
|
artikel
|
| 129 |
Microdialysis in peripheral tissues
|
de la Peña, Amparo
|
|
2000
|
69-70 |
2-3 |
p. 189-216
28 p.
|
artikel
|
| 130 |
Microdialysis in the study of drug transporters in the CNS
|
Sawchuk, Ronald J
|
|
2000
|
69-70 |
2-3 |
p. 295-307
13 p.
|
artikel
|
| 131 |
Microparticles and polymers for the mucosal delivery of vaccines
|
O'Hagan, Derek T.
|
|
1998
|
69-70 |
2-3 |
p. 305-320
16 p.
|
artikel
|
| 132 |
Microparticle targeting to M cells
|
Ermak, Thomas H
|
|
1998
|
69-70 |
2-3 |
p. 261-283
23 p.
|
artikel
|
| 133 |
Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo)
|
Papisov, Mikhail I.
|
|
1995
|
69-70 |
2-3 |
p. 127-139
13 p.
|
artikel
|
| 134 |
Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC)
|
Siepmann, J
|
|
2001
|
69-70 |
2-3 |
p. 139-157
19 p.
|
artikel
|
| 135 |
Modeling transdermal drug release
|
Kalia, Yogeshvar N.
|
|
2001
|
69-70 |
2-3 |
p. 159-172
14 p.
|
artikel
|
| 136 |
Model systems in iontophoresis — transport efficacy
|
Sage Jr., Burton H.
|
|
1992
|
69-70 |
2-3 |
p. 265-287
23 p.
|
artikel
|
| 137 |
Modulation of pharmacokinetic behavior of liposomes
|
Scherphof, Gerrit L.
|
|
1997
|
69-70 |
2-3 |
p. 179-191
13 p.
|
artikel
|
| 138 |
Molecular conformation and structural reorganization near the lipid bilayer surface: biophysical studies of ‘long-circulating’ and DNA-carrying membranes
|
Cevc, Gregor
|
|
1997
|
69-70 |
2-3 |
p. 233-
1 p.
|
artikel
|
| 139 |
Mucosal immunity of the gastrointestinal tract and oral tolerance
|
Simecka, Jerry W
|
|
1998
|
69-70 |
2-3 |
p. 235-259
25 p.
|
artikel
|
| 140 |
Nano- and microparticles for the delivery of polypeptides and proteins
|
Couvreur, P.
|
|
1993
|
69-70 |
2-3 |
p. 141-162
22 p.
|
artikel
|
| 141 |
New lipo-PGE1 using a stable prodrug of prostaglandin E1 (PGE1)
|
Igarashi, R.
|
|
1996
|
69-70 |
2-3 |
p. 189-194
6 p.
|
artikel
|
| 142 |
Noncompartmentally-based pharmacokinetic modeling
|
Veng-Pedersen, Peter
|
|
2001
|
69-70 |
2-3 |
p. 265-300
36 p.
|
artikel
|
| 143 |
Non-viral siRNA delivery to the lung
|
Thomas, Mini
|
|
2007
|
69-70 |
2-3 |
p. 124-133
10 p.
|
artikel
|
| 144 |
Novel approaches to design and deliver safe and effective antiglaucoma agents to the eye
|
Reddy, Indra K.
|
|
1994
|
69-70 |
2-3 |
p. 251-267
17 p.
|
artikel
|
| 145 |
Oligonucleotide therapeutics: lessons from sterically stabilized liposomes
|
Woodle, M.C.
|
|
1997
|
69-70 |
2-3 |
p. 273-
1 p.
|
artikel
|
| 146 |
On mathematical models of microdialysis: geometry, steady-state models, recovery and probe radius
|
Ståhle, Lars
|
|
2000
|
69-70 |
2-3 |
p. 149-167
19 p.
|
artikel
|
| 147 |
Opportunities and challenges for therapeutic gene silencing using RNAi and microRNA technologies
|
Akhtar, Saghir
|
|
2007
|
69-70 |
2-3 |
p. 73-74
2 p.
|
artikel
|
| 148 |
Oral insulin delivery 1 Abbreviations: GI, gastrointestinal; IDDM, insulin-dependent diabetes mellitus; IU, international units; NIDDM, non-insulin-dependent diabetes mellitus; PIN, phase inversion nanoencapsulation; ZOT, zona occludens toxin. 1
|
Carino, Gerardo P
|
|
1999
|
69-70 |
2-3 |
p. 249-257
9 p.
|
artikel
|
| 149 |
Oral particulate delivery: status and future trends
|
Chen, Hongming
|
|
1998
|
69-70 |
2-3 |
p. 339-350
12 p.
|
artikel
|
| 150 |
Pathogenesis of non-insulin-dependent (type II) diabetes mellitus (NIDDM) – genetic predisposition and metabolic abnormalities
|
Jun, Hee-Sook
|
|
1999
|
69-70 |
2-3 |
p. 157-177
21 p.
|
artikel
|
| 151 |
Pathogenesis, prediction and trials for the prevention of insulin-dependent (type 1) diabetes mellitus 1 Abbreviations: s.c., subcutaneous; i.p., intraperitoneal; i.v., intravenous; IFA, incomplete Freund's adjuvant; DTP, diphtheria-tetanus-pertussis; LCMV, lymphocytic choriomeningitis virus; GAD, glutamic acid decarboxylase; ICA, islet cell autoantibody; JDF, juvenile diabetes foundation; IAA, insulin autoantibody; GAA, glutamic acid decarboxylase autoantibody; DM, diabetes mellitus; RIA, radioimmunoassay; AA, autoantibody; kD, kilodalton; FPIR, first phase insulin release; IIF, indirect immunofluoresence; IGT, impaired glucose tolerance; OGT, oral glucose tolerance. 1
|
Graves, Patricia M.
|
|
1999
|
69-70 |
2-3 |
p. 143-156
14 p.
|
artikel
|
| 152 |
Penetration of neurotrophins and cytokines across the blood–brain/blood–spinal cord barrier
|
Pan, Weihong
|
|
1999
|
69-70 |
2-3 |
p. 291-298
8 p.
|
artikel
|
| 153 |
Peptide nucleic acids: versatile tools for gene therapy strategies
|
Dean, David A
|
|
2000
|
69-70 |
2-3 |
p. 81-95
15 p.
|
artikel
|
| 154 |
P-Glycoprotein, a gatekeeper in the blood–brain barrier
|
Schinkel, Alfred H
|
|
1999
|
69-70 |
2-3 |
p. 179-194
16 p.
|
artikel
|
| 155 |
Pharmacokinetics of long-circulating liposomes
|
Allen, Theresa M.
|
|
1995
|
69-70 |
2-3 |
p. 267-284
18 p.
|
artikel
|
| 156 |
Physical properties and tissue distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes
|
Sadzuka, Yasuyuki
|
|
1997
|
69-70 |
2-3 |
p. 257-263
7 p.
|
artikel
|
| 157 |
Physiological considerations in the design of particulate dosage forms for oral vaccine delivery
|
Yeh, Ping-Yang
|
|
1998
|
69-70 |
2-3 |
p. 123-133
11 p.
|
artikel
|
| 158 |
Plasma factors affecting disposition of liposomes
|
Kiwada, Hiroshi
|
|
1997
|
69-70 |
2-3 |
p. 193-199
7 p.
|
artikel
|
| 159 |
Polymeric carriers for oral uptake of microparticulates
|
Andrianov, Alexander K
|
|
1998
|
69-70 |
2-3 |
p. 155-170
16 p.
|
artikel
|
| 160 |
Polymeric implants for cancer chemotherapy
|
Fung, Lawrence K.
|
|
1997
|
69-70 |
2-3 |
p. 209-230
22 p.
|
artikel
|
| 161 |
Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics
|
Allémann, Eric
|
|
1998
|
69-70 |
2-3 |
p. 171-189
19 p.
|
artikel
|
| 162 |
Polymers for controlled parenteral delivery of peptides and proteins
|
Heller, Jorge
|
|
1993
|
69-70 |
2-3 |
p. 163-204
42 p.
|
artikel
|
| 163 |
Preface
|
Gibson, N.W
|
|
1997
|
69-70 |
2-3 |
p. 69-70
2 p.
|
artikel
|
| 164 |
Preface
|
Pitt, C.G.
|
|
1993
|
69-70 |
2-3 |
p. vii-
1 p.
|
artikel
|
| 165 |
Preface
|
Guy, Richard H.
|
|
1992
|
69-70 |
2-3 |
p. vii-viii
nvt p.
|
artikel
|
| 166 |
Preface
|
Torchilin, Vladimir P.
|
|
1995
|
69-70 |
2-3 |
p. 125-126
2 p.
|
artikel
|
| 167 |
Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems
|
Bodor, Nicholas
|
|
1999
|
69-70 |
2-3 |
p. 229-254
26 p.
|
artikel
|
| 168 |
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting
|
Rensen, Patrick C.N
|
|
2001
|
69-70 |
2-3 |
p. 251-276
26 p.
|
artikel
|
| 169 |
Renal secretion of organic cations: a multistep process
|
Pritchard, John B.
|
|
1997
|
69-70 |
2-3 |
p. 231-242
12 p.
|
artikel
|
| 170 |
Renal secretion of xenobiotics mediated by P-glycoprotein: Importance to renal function in health and exploitation for targeted drug delivery to epithelial cysts in polycystic kidney disease
|
Simmons, Nicholas L.
|
|
1997
|
69-70 |
2-3 |
p. 243-256
14 p.
|
artikel
|
| 171 |
Renal tubular secretion of organic anions
|
Dantzler, William H.
|
|
1997
|
69-70 |
2-3 |
p. 217-230
14 p.
|
artikel
|
| 172 |
Ribozyme and peptide–nucleic acid-based gene therapy
|
Phylactou, Leonidas A
|
|
2000
|
69-70 |
2-3 |
p. 97-108
12 p.
|
artikel
|
| 173 |
RNA interference and innate immunity
|
Sioud, Mouldy
|
|
2007
|
69-70 |
2-3 |
p. 153-163
11 p.
|
artikel
|
| 174 |
RNAi therapeutics: Principles, prospects and challenges
|
Aagaard, Lars
|
|
2007
|
69-70 |
2-3 |
p. 75-86
12 p.
|
artikel
|
| 175 |
RNA repair: a novel approach to gene therapy
|
Watanabe, Takashi
|
|
2000
|
69-70 |
2-3 |
p. 109-118
10 p.
|
artikel
|
| 176 |
Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system
|
Suzuki, Hiroshi
|
|
1997
|
69-70 |
2-3 |
p. 257-285
29 p.
|
artikel
|
| 177 |
Role of saccharides for the freeze-thawing and freeze drying of liposome
|
Miyajima, Koichiro
|
|
1997
|
69-70 |
2-3 |
p. 151-159
9 p.
|
artikel
|
| 178 |
Roles of lipid polymorphism in intracellular delivery
|
Hafez, Ismail M.
|
|
2001
|
69-70 |
2-3 |
p. 139-148
10 p.
|
artikel
|
| 179 |
Screening and biological evaluation of liposomal formulations containing Adriamycin®
|
Yachi, Kiyoto
|
|
1997
|
69-70 |
2-3 |
p. 123-131
9 p.
|
artikel
|
| 180 |
Selective boron drug delivery to brain tumors for boron neutron capture therapy
|
Chen, Wei
|
|
1997
|
69-70 |
2-3 |
p. 231-247
17 p.
|
artikel
|
| 181 |
shRNA and siRNA delivery to the brain
|
Pardridge, William M.
|
|
2007
|
69-70 |
2-3 |
p. 141-152
12 p.
|
artikel
|
| 182 |
Site-specific insulin conjugates with enhanced stability and extended action profile
|
Uchio, Takashi
|
|
1999
|
69-70 |
2-3 |
p. 289-306
18 p.
|
artikel
|
| 183 |
Skin biological issues in electrically enhanced transdermal delivery
|
Ledger, Philip W.
|
|
1992
|
69-70 |
2-3 |
p. 289-307
19 p.
|
artikel
|
| 184 |
Soft anticholinergics
|
Hammer, R.H.
|
|
1994
|
69-70 |
2-3 |
p. 281-292
12 p.
|
artikel
|
| 185 |
Solid lipid nanoparticles
|
Mehnert, Wolfgang
|
|
2001
|
69-70 |
2-3 |
p. 165-196
32 p.
|
artikel
|
| 186 |
Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract
|
Ponchel, Gilles
|
|
1998
|
69-70 |
2-3 |
p. 191-219
29 p.
|
artikel
|
| 187 |
Stability of lipid emulsions for drug delivery
|
Washington, C.
|
|
1996
|
69-70 |
2-3 |
p. 131-145
15 p.
|
artikel
|
| 188 |
Stealth® liposomes: from theory to product
|
Cˇeh, Boris
|
|
1997
|
69-70 |
2-3 |
p. 165-177
13 p.
|
artikel
|
| 189 |
Sterically stabilized liposome therapeutics
|
Woodle, Martin C.
|
|
1995
|
69-70 |
2-3 |
p. 249-265
17 p.
|
artikel
|
| 190 |
Structure-transport relationships in transdermal iontophoresis
|
Yoshida, Nagahiro H.
|
|
1992
|
69-70 |
2-3 |
p. 239-264
26 p.
|
artikel
|
| 191 |
Studies on two new lymph imaging agents and their clinical application
|
Ma, Yuan-Ming
|
|
1997
|
69-70 |
2-3 |
p. 315-323
9 p.
|
artikel
|
| 192 |
Supramolecular lipidic drug delivery systems: From laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B
|
Hillery, Anya M.
|
|
1997
|
69-70 |
2-3 |
p. 345-363
19 p.
|
artikel
|
| 193 |
Surface-modified liposomes in gamma- and MR-imaging
|
Torchilin, Vladimir P.
|
|
1997
|
69-70 |
2-3 |
p. 301-313
13 p.
|
artikel
|
| 194 |
Systemic siRNA delivery via hydrodynamic intravascular injection
|
Lewis, David L.
|
|
2007
|
69-70 |
2-3 |
p. 115-123
9 p.
|
artikel
|
| 195 |
Targeting efficiency of PEG-immunoliposome-conjugated antibodies at PEG terminals
|
Maruyama, Kazuo
|
|
1997
|
69-70 |
2-3 |
p. 235-242
8 p.
|
artikel
|
| 196 |
Targeting penicillins to the central nervous system: chemical delivery systems and redox analogs
|
Pop, E.
|
|
1994
|
69-70 |
2-3 |
p. 211-226
16 p.
|
artikel
|
| 197 |
The barrier function of CYP3A4 and P-glycoprotein in the small bowel
|
Watkins, Paul B
|
|
1997
|
69-70 |
2-3 |
p. 161-170
10 p.
|
artikel
|
| 198 |
The blood–brain barrier efflux transporters as a detoxifying system for the brain
|
Terasaki, Tetsuya
|
|
1999
|
69-70 |
2-3 |
p. 195-209
15 p.
|
artikel
|
| 199 |
The brain-targeted delivery of dopamine using a redox-based chemical delivery system
|
Simpkins, James W.
|
|
1994
|
69-70 |
2-3 |
p. 243-249
7 p.
|
artikel
|
| 200 |
The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres
|
Gref, R.
|
|
1995
|
69-70 |
2-3 |
p. 215-233
19 p.
|
artikel
|
| 201 |
The design and development of DaunoXome® for solid tumor targeting in vivo
|
Forssen, Eric A.
|
|
1997
|
69-70 |
2-3 |
p. 133-150
18 p.
|
artikel
|
| 202 |
The distribution and chemical kinetics of prostaglandin E1 in lipid emulsions
|
Teagarden, Dirk L.
|
|
1996
|
69-70 |
2-3 |
p. 155-164
10 p.
|
artikel
|
| 203 |
The effect of physical barriers and properties on the oral absorption of particulates
|
Norris, Daniel A
|
|
1998
|
69-70 |
2-3 |
p. 135-154
20 p.
|
artikel
|
| 204 |
The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans
|
Wilkinson, Grant R
|
|
1997
|
69-70 |
2-3 |
p. 129-159
31 p.
|
artikel
|
| 205 |
Theoretical models for iontophoretic delivery
|
Kasting, Gerald B.
|
|
1992
|
69-70 |
2-3 |
p. 177-199
23 p.
|
artikel
|
| 206 |
The pharmaceutics and delivery of therapeutic polypeptides and proteins
|
Talmadge, James E.
|
|
1993
|
69-70 |
2-3 |
p. 247-299
53 p.
|
artikel
|
| 207 |
The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids
|
Loftsson, Thorsteinn
|
|
1994
|
69-70 |
2-3 |
p. 293-299
7 p.
|
artikel
|
| 208 |
The preparation and characterization of polymeric antigen delivery systems for oral administration
|
Singh, Manmohan
|
|
1998
|
69-70 |
2-3 |
p. 285-304
20 p.
|
artikel
|
| 209 |
Therapeutic potential for microRNAs
|
Esau, Christine C.
|
|
2007
|
69-70 |
2-3 |
p. 101-114
14 p.
|
artikel
|
| 210 |
The role of CpG motifs in immunostimulation and gene therapy
|
Scheule, Ronald K
|
|
2000
|
69-70 |
2-3 |
p. 119-134
16 p.
|
artikel
|
| 211 |
The role of electroosmotic flow in transdermal iontophoresis
|
Pikal, Michael J.
|
|
1992
|
69-70 |
2-3 |
p. 201-237
37 p.
|
artikel
|
| 212 |
The use of microdialysis in CNS drug delivery studies
|
Hammarlund-Udenaes, Margareta
|
|
2000
|
69-70 |
2-3 |
p. 283-294
12 p.
|
artikel
|
| 213 |
The use of phage display for the development of tumour targeting agents
|
Nilsson, Fredrik
|
|
2000
|
69-70 |
2-3 |
p. 165-196
32 p.
|
artikel
|
| 214 |
Three-dimensional liposome networks: freeze fracture electron microscopical evaluation of their structure and in vitro analysis of release of hydrophilic markers
|
Brandl, M.
|
|
1997
|
69-70 |
2-3 |
p. 161-164
4 p.
|
artikel
|
| 215 |
Tissue engineering via local gene delivery:
|
Bonadio, Jeffrey
|
|
2000
|
69-70 |
2-3 |
p. 185-194
10 p.
|
artikel
|
| 216 |
Toward development of a non-viral gene therapeutic
|
Smith, Janet
|
|
1997
|
69-70 |
2-3 |
p. 135-150
16 p.
|
artikel
|
| 217 |
Toward lung-selective β2-adrenergic bronchodilator prodrugs
|
Svensson, Leif-Å.
|
|
1994
|
69-70 |
2-3 |
p. 319-330
12 p.
|
artikel
|
| 218 |
Towards new products for human health
|
Hirota, Sadao
|
|
1997
|
69-70 |
2-3 |
p. 121-122
2 p.
|
artikel
|
| 219 |
Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity
|
Akhtar, Saghir
|
|
2007
|
69-70 |
2-3 |
p. 164-182
19 p.
|
artikel
|
| 220 |
Transcriptional control: an essential component of cancer gene therapy strategies?
|
Harrington, Kevin J.
|
|
2000
|
69-70 |
2-3 |
p. 167-184
18 p.
|
artikel
|
| 221 |
Transdermal ion migration
|
Bradley Phipps, J.
|
|
1992
|
69-70 |
2-3 |
p. 137-176
40 p.
|
artikel
|
| 222 |
Treatment of type I diabetes using encapsulated islets 1 Abbreviations: Tx, transplantation; IEQ, islet equivalent; BUN, blood urea nitrogen. 1
|
Soon-Shiong, Patrick
|
|
1999
|
69-70 |
2-3 |
p. 259-270
12 p.
|
artikel
|
| 223 |
Uptake and adjuvant activity of orally delivered saponin and ISCOM™ vaccines
|
Sjölander, Anders
|
|
1998
|
69-70 |
2-3 |
p. 321-338
18 p.
|
artikel
|
| 224 |
Use of microdialysis in drug delivery studies
|
Elmquist, William F
|
|
2000
|
69-70 |
2-3 |
p. 123-124
2 p.
|
artikel
|
| 225 |
Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents
|
Trubetskoy, Vladimir S.
|
|
1995
|
69-70 |
2-3 |
p. 311-320
10 p.
|
artikel
|
| 226 |
Vector-mediated drug delivery to the brain
|
Pardridge, William M.
|
|
1999
|
69-70 |
2-3 |
p. 299-321
23 p.
|
artikel
|
| 227 |
Virosomes: evolution of the liposome as a targeted drug delivery system
|
Kaneda, Yasufumi
|
|
2000
|
69-70 |
2-3 |
p. 197-205
9 p.
|
artikel
|
| 228 |
What are the pathways of iontophoretic current flow through mammalian skin?
|
Cullander, Christopher
|
|
1992
|
69-70 |
2-3 |
p. 119-135
17 p.
|
artikel
|
| 229 |
Which polymers can make nanoparticulate drug carriers long-circulating?
|
Torchilin, Vladimir P.
|
|
1995
|
69-70 |
2-3 |
p. 141-155
15 p.
|
artikel
|
Tijdschrift beschrijving